Gemcitabine-associated livedoid thrombotic microangiopathy with associated sclerema neonatorum-like microscopic changes.

J Cutan Pathol 2012 Jul 22;39(7):707-11. Epub 2012 May 22.

Department of Dermatology, University Hospital of Salamanca, Salamanca, Spain.

Gemcitabine is a deoxycytidine analog antimetabolite that is now accepted as first-line treatment for advanced and metastatic pancreatic carcinoma. Gemcitabine-related thrombotic microangiopathy associated with systemic hemolytic-uremic syndrome or thrombotic thrombocytopenia purpura has rarely been described. Herein, we report a patient who developed a livedoid thrombotic microangiopathy with no signs of associated hemolytic-uremic syndrome. Cutaneous thrombotic microangiopathy occurred after the administration of his 17th cycle and a cumulative dose of 53.65 g/m(2) of gemcitabine. Some authors have suggested that this toxicity may be dose-related, and a 10th cycle or a cumulative dose of 9-56 g/m(2) have been proposed as the prothrombotic threshold. Interestingly, dermatopathologic findings were limited to the subcutis and they consisted of small-vessel occlusion by intravascular fibrin and leukocytes, vessel wall thickening and endothelial cell swelling. Surprisingly, we observed some structures arranged radially with needle-shaped clefts resembling those of sclerema neonatorum. Awareness of this potential cutaneous toxicity by dermatologists and dermatopathologists is extremely important.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0560.2012.01918.xDOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
July 2012
11 Reads

Publication Analysis

Top Keywords

thrombotic microangiopathy
16
cumulative dose
8
microangiopathy associated
8
hemolytic-uremic syndrome
8
cycle cumulative
8
livedoid thrombotic
8
thrombotic
5
dose 9-56
4
9-56 g/m2
4
dose-related 10th
4
10th cycle
4
prothrombotic threshold
4
dermatopathologic findings
4
findings limited
4
interestingly dermatopathologic
4
threshold interestingly
4
proposed prothrombotic
4
toxicity dose-related
4
g/m2 proposed
4
g/m2 gemcitabine
4

References

(Supplied by CrossRef)
Advanced pancreatic carcinoma: current treatment and future challenges.
Stathis et al.
Nat Rev Clin Oncol 2010
Gemcitabine-associated thrombotic microangiopathy.
Humphreys et al.
Cancer 2004
Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma.
Willemsen et al.
Acta Oncol 2011
Gemcitabine: vascular toxicity and prothrombotic potential.
Dasanu et al.
Expert Opin Drug Saf 2008
Gemcitabine and haemolytic-uraemic syndrome.
Ruiz et al.
Ann Oncol 2004
Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies.
Moake et al.
Best Pract Res Clin Haematol 2009
Cutaneous vasculitis associated with gemcitabine therapy.
Corella et al.
Clin Exp Dermatol 2009
Gemcitabine induced digital ischaemia and necrosis.
Holstein et al.
Eur J Cancer Care (Engl) 2010
Erysipeloid skin toxicity induced by gemcitabine.
Zustovich et al.
J Eur Acad Dermatol Venereol 2006
Gemcitabine-associated scleroderma-like changes of the lower extremities.
Bessis et al.
J Am Acad Dermatol 2004
Linear immunoglobulin A bullous dermatosis induced by gemcitabine.
del Pozo et al.
Ann Pharmacother 2001

Similar Publications